-
Ferring announces recipients of 2018-19 Innovation Grants
-Ferring Pharmaceuticals today announced the recipients of the 2018-19 Ferring Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego.
-
Ferring announces retirement of Michel Pettigrew, President of the Executive Board and Chief Operating Officer
-Ferring Pharmaceuticals today announced that Michel Pettigrew, President of the Executive Board and Chief Operating Officer…
-
Ferring Pharmaceuticals and Evotec AG form strategic research alliance in reproductive medicine and women’s health
-Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance…
-
Ferring and Celmatix launch ambitious genomics collaboration to advance care in reproductive medicine and women’s health
-Ferring Pharmaceuticals and Celmatix today announced an ambitious genomics collaboration aimed at uncovering new insights into ovarian…
-
New analysis of Rekovelle® data further supports use of AMH to personalise fertility treatment
-Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial…
-
Ferring’s heat-stable carbetocin could save thousands of women’s lives by preventing excessive bleeding after childbirth
-Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin…
-
Ferring signs global agreement to commercialise novel gene therapy for bladder cancer patients
-Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure…
-
Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.
-Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring…
-
Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day
-On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia…
-
Ferring announces positive outcome of European Decentralised Procedure (DCP) for Testavan®, a treatment for men with hypogonadism
-Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan®…
PRESS RELEASE 2018
PRESS RELEASE 2018